MyAverix Finance MyAverix Finance

ST · Healthcare

Stayble Therapeutics AB (STABL)

Biotechnology

Stayble Therapeutics AB (STABL) is listed on ST in the Healthcare sector. Industry: Biotechnology. As of 2026-05-24, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-05-24

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for STABL

P/E ratio
25.00

Stayble Therapeutics AB (STABL) — FAQ

What is STABL's P/E ratio?

The price-to-earnings (P/E) ratio for Stayble Therapeutics AB (STABL) is 25.00 (data as of 2026-05-24).

Does Stayble Therapeutics AB pay a dividend?

Dividend yield is not available in the current snapshot for Stayble Therapeutics AB (STABL). Check the MyAverix Finance app for the latest dividend data.

What sector is Stayble Therapeutics AB in?

Stayble Therapeutics AB (STABL) is classified in the Healthcare sector (Biotechnology industry).

What exchange is STABL listed on?

STABL is listed on ST.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play